From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.
Patients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain low. We review the literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis. The medical board of the National Psoriasis Foundation recommends that dermatologists counsel patients on updating vaccinations in accordance with recommendations of the Advisory Committee for Immunization Practices as any measures taken to prevent infection can increase the safety of immunomodulatory therapies.
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Lara
L
Wine-Lee
Sara C
SC
Keller
Marissa B
MB
Wilck
Stephen J
SJ
Gluckman
Abby S
AS
Van Voorhees
D000075202:Contraindications; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008727:Methotrexate / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000188:drug therapy*; D012307:Risk Factors; D014195:Travel; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014611:Vaccination
D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate
CDC; Centers for Disease Control and Prevention; HBV; HPV; IBD; IL; MMR; TNF; biologics; cyclosporine; hepatitis B virus; human papillomavirus; immunosuppressive therapy; inactivated vaccine; inflammatory bowel disease; interleukin; live vaccine; measles, mumps, and rubella; methotrexate; tumor necrosis factor; vaccine administration; vaccine counseling